NCT07416188 2026-04-16
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Not yet recruiting
Clinical Trials
12 trialsNCT07510100 2026-04-03
FUMANBA-04
Nanjing IASO Biotechnology Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07502768 2026-03-31
EpiRev-NKT
Fudan University
Phase 1/2 Not yet recruiting
NCT06639607 2026-03-10
PRiME II
Washington University School of Medicine
Phase 1/2 Not yet recruiting
NCT07288814 2025-12-17
Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT07206563 2025-10-03
Penfluridol for Relapsed/Refractory Small Cell Cancers
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Not yet recruiting
NCT06281847 2025-09-18
RESOLVE AML001
Advesya SAS
Phase 1/2 Not yet recruiting
NCT07107204 2025-09-17
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Biotroy Therapeutics
Phase 1/2 Not yet recruiting
NCT07175415 2025-09-16
HEM-iSMART E
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Not yet recruiting
NCT06845241 2025-02-25
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06180499 2024-02-14
ILDTreg2
Assistance Publique - Hôpitaux de Paris
Phase 1/2 Not yet recruiting
NCT05503888 2022-08-17
Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Not yet recruiting